Differing patterns of influenza activity in the southern hemisphere during and between the 2009 pandemic and the 2010 winter influenza season – the usefulness for EuropeArchived
This is timely comparison carried out at the end of the 2010 southern hemisphere winter.
Are statins protective in patients with severe respiratory infections? Two new studies from EuropeArchived
In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
Case inventory study from Sweden concerning association of Pandemrix vaccination and reports of narcolepsy with cataplexy in children and adolescentsArchived
ECDC has previously summarised information concerning the appearance of narcolepsy following the use of a specific pandemic vaccine (Pandemrix®) in children and adolescents in three European Countries.
EMA's Committee for Medicinal Products for Human Use (CHMP) issues opinion on narcolepsy and vaccination with Pandemrix®Archived
On 21 July 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued its opinion on the review of Pandemrix® and reports on narcolepsy. The CHMP recommended that in persons under 20 years of age Pandemrix® may only be used if the recommended seasonal trivalent influenza vaccine is not available and if immunisation against H1N1 is still needed (e.g. in persons at risk of the complications of infection).
Recommendation by the European Medicines Agency concerning Pandemrix vaccination and reports of narcolepsy in children and adolescentsArchived
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.
Surveillance and immunisation are keys to protect Europe against seasonal influenzaArchived
The 2011 seasonal influenza immunisation campaigns have started across Europe. As in previous years ECDC is marking the start of the 2011-12 surveillance season in Week 40 with the publication of regular weekly updates of the main epidemiological and virological developments in the Weekly Influenza Surveillance Overview (WISO).
Influenza vaccine effectiveness: results of the ECDC/I-MOVE studies and other studiesArchived
On the 26 October 2011, The Lancet Infectious Diseases published a systematic review and a meta-analysis, combining the results of several studies undertaken on influenza vaccine effectiveness.
Systematic review and meta-analysis concerning the efficacy and effectiveness of seasonal influenza vaccines – (part 1)Archived
This is an authoritative independent evidence-based review and meta-analysis of the efficacy and effectiveness of influenza vaccines. It confines itself to trials and observational studies where diagnostic tests confirmed influenza infection as the end point.
Overall and stratified estimates of influenza vaccine effectiveness in Europe for the season 2010-2011Archived
This paper gives the results from the third season of the ‘Influenza Monitoring Vaccine Effectiveness in Europe’ (I-MOVE) Project.